2008-10-07 17:18:00 -

www.rtix.com - RTI Biologics, Inc. (RTI) (Nasdaq:RTIX), the Florida-based processor of orthopedic, dental, hernia and other biologic implants, announced today that the company's bovine pericardium membrane has been introduced into the dental market through its distributor, Zimmer Dental, under the trade name CopiOs(R). The product was introduced at the American Academy of Periodontology and the American

Association of Oral and Maxillofacial Surgeons annual meetings, both held in Seattle, Wash. in September.

The CopiOs Pericardium Membrane will address the needs of oral surgeons, periodontists and dentists in conjunction with bone grafting and implant procedures. RTI partners with Zimmer Dental, a worldwide leader in the dental implant business, in the rapidly growing dental biologics market.

The membrane is used in various oral surgical procedures, including guided bone regeneration (GBR). The bovine pericardium membrane implant received 510(k) clearance for dental applications from the Food and Drug Administration (FDA) in the second quarter of 2008.

"We have been extremely pleased with the efforts of our distributor, Zimmer Dental, and are excited to bring a global, xenograft solution to the dental business," said Guy Mayer, president of RTI. "We have expanded our biologic options in order to provide customers with a full range of solutions and are excited about continuing our growth in this business."

About RTI Biologics Inc.

RTI Biologics, Inc. is the leading provider of sterile biological implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening, precision shaping and proprietary, validated sterilization processes. These allograft and xenograft implants are used in orthopedic, dental, hernia and other specialty surgeries.

RTI's innovations continuously raise the bar of science and safety for biologics--from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing fully validated sterilization processes that include viral inactivation steps. Two such processes, the BioCleanse(R) Tissue Sterilization Process and the Tutoplast(R) process, sterilize tissue, are clinically successful and are scientifically proven to eliminate donor-to-recipient disease transmission risk while preserving tissue strength and biocompatibility. These processes have a proven record of more than two million implants distributed with zero incidence of infection. In addition, RTI pastes are sterilized through the demineralization process, a validated viral inactivation step.

The company is leading the evolution of biologics once again by offering a bovine based biological matrix, providing surgeons an expanded supply of safe, sterile tissue for their patients.

RTI's worldwide corporate headquarters are located in Alachua, Fla., with international facilities in Neunkirchen, Germany, and Aix-en-Provence, France. The company is accredited by the American Association of Tissue Banks.

Forward Looking Statement

This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements about the expected benefits of the business combination involving RTI and Tutogen, including potential synergies and cost savings, future financial and operating results, and the combined company's plans and objectives. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results, regulatory approvals or changes to agreements with distributors also are forward-looking statements. Forward-looking statements are subject to risks and uncertainties, including the ability of RTI to integrate its business successfully and to realize the expected synergies and cost savings from the merger and the risks described in public filings on file with the Securities and Exchange Commission (SEC). Actual results may differ materially from anticipated results reflected in these forward-looking statements. Copies of the company's SEC filings may be obtained by contacting the company or the SEC or by visiting RTI's Web site at www.rtix.com or the SEC's Web site at www.sec.gov.

RTI Biologics, Inc., Alachua
Wendy Crites Wacker, APR, Corporate Communications
386-418-8888